Tirzepatide and the risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials

1 September 2025 (14:15 - 15:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speakers

Doctor Ensieh Sadat Mansouri

Tehran University of Medical Sciences, Tehran (Iran (Islamic Republic of))

Mr Lucas Barbosa

Hospital das Clinicas da UFMG, Belo Horizonte (Brazil)

4 More presentations in this session

Presentation thumbnail

Progressive disease substrate in obese type 2 diabetic patients with coronary artery disease despite achieving HbA1c <7.0%: sub-analysis from the OPTIMAL randomized study

Doctor A. Salib (Melbourne, AU)

Abstract Slides Video

Presentation thumbnail

GLP-1 receptor agonists and SGLT2-inhibitors in patients with diabetes and ischaemic heart disease in primary care

Doctor T. Andersson (Gothenburg, SE)

Abstract Slides Video

Presentation thumbnail

Use of cardioprotective glucose lowering therapy before and after myocardial infarction among patients with type-2 diabetes: a nationwide registry study

Ms B. Sharad (Malmo, SE)

Abstract Slides Video

Presentation thumbnail

The impact of age of onset and duration of Type 2 diabetes on life expectancy and serious health outcomes

Doctor J. Isufi (Gothenburg, SE)

Abstract Slides

Access the full session

Session thumbnail

Diabetes and the heart (3)

The Event

Event poster

ESC Congress 2025

1 September 2025 14:15 CET

You may be interested in

Congress Session

Integrated management of atrial fibrillation: addressing comorbidities, risk factors, and lifestyle

Congress Presentation

Effect of glucagon-like peptide-1 receptor agonists on atrial fibrillation incidence: a systematic review and meta-analysis

Congress Presentation

Semaglutide and atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources